Clinical trial · Observational
Patient Factors Impacting Adherence to Oral Chemotherapy
A Pilot Study to Identify Patient Factors Impacting Adherence to Oral Chemotherapy
NCT01487343CI-TRIAL-00024750completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to identify what makes it easier and what makes it harder to take oral chemotherapy.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Gastrointestinal Cancer | Malignant Digestive System Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| questionnaire and interview | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- breast or gastrointestinal cancer pts taking capecitabine
- description
- This is a mixed-methodology pilot study of patients currently taking oral chemotherapy for breast or gastrointestinal cancer. The quantitative portion of the study consists of self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions.
- interventionNames
- Behavioral: questionnaire and interview
Primary outcomes (1)
- measure
- adherence to oral chemotherapy
- timeFrame
- 1 year
- description
- Participation in the study entails completion of five short questionnaires related to the medication adherence (Medication Adherence Questionnaire), beliefs about medication (Beliefs about Medications Questionnaire), side effect experience (Frequency, Intensity, and Burden of Side Effects Rating), self-efficacy (Self-efficacy for Appropriate Medication Use) and satisfaction with medication information (Satisfaction with Information about Medicines Scale) as well as a demographic and treatment data sheet.
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * Diagnosis of primary breast cancer or gastrointestinal cancer * Currently prescribed capecitabine * Age 21 years or older * Able to understand written and oral English Exclusion Criteria: * Major psychopathology or cognitive impairment likely in the judgment of the research staff to interfere with the participation or completion of the protocol.
References
Publications (0)
Data not yet available
No reference posted for this study.